164 related articles for article (PubMed ID: 19382393)
41. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
42. Dasatinib: for some difficult cases of adult leukaemia.
Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
[No Abstract] [Full Text] [Related]
43. Clofarabine for treatment of acute lymphoblastic leukaemia in adults.
Rodríguez Vargas B; Sánchez Cuervo M; Bermejo Vicedo T
Farm Hosp; 2011; 35(1):47-9. PubMed ID: 20673734
[No Abstract] [Full Text] [Related]
44. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
45. Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature.
Sigalas P; Tourvas AD; Moulakakis A; Pangalis G; Kontopidou F
Leuk Res; 2009 Jul; 33(7):e61-3. PubMed ID: 19157550
[No Abstract] [Full Text] [Related]
46. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.
Jeha S
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1137-44, viii. PubMed ID: 19825457
[TBL] [Abstract][Full Text] [Related]
47. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Hartz B; Löbel U; Hagel C; Escherich G
Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
[No Abstract] [Full Text] [Related]
48. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
49. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
51. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
Baytan B; Ozdemir O; Gunes AM; Dönmez O
J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324
[TBL] [Abstract][Full Text] [Related]
52. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
53. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
[TBL] [Abstract][Full Text] [Related]
54. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia.
Ghara N; Saha V
Lancet Haematol; 2023 Jun; 10(6):e391-e393. PubMed ID: 37167993
[No Abstract] [Full Text] [Related]
55. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
56. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
[TBL] [Abstract][Full Text] [Related]
57. MR imaging in nelarabine-induced myelopathy.
Dua SG; Jhaveri MD
J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
[TBL] [Abstract][Full Text] [Related]
58. Clinical trials referral resource. Clinical trials using compound 506U78.
Ho PT; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 Dec; 10(12):1831-2. PubMed ID: 9063861
[No Abstract] [Full Text] [Related]
59. Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions.
Burley K; Wolf J; Raffoux E; Marks DI
Bone Marrow Transplant; 2018 Mar; 53(3):344-346. PubMed ID: 29269798
[No Abstract] [Full Text] [Related]
60. Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
Prescrire Int; 2009 Apr; 18(100):49-52. PubMed ID: 19585712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
